Protein Design & Engineering in Biopharma Summit 2026

Protein Design & Engineering in Biopharma Summit 2026 is organized by Hanson Wade and will be held from Nov 10 - 12, 2026 at Wyndham Boston Beacon Hill, Boston, Massachusetts, United States of America.

Description:
Harnessing Computational, Structural & Biophysical Insight to Design, Engineer & Optimize Proteins with Enhanced Function, Stability, Therapeutic & Developability Potential

Advances in protein language models, generative design, structural biology, high-throughput experimentation and protein analytics are rapidly expanding the possibilities of therapeutic protein engineering. Yet as designed proteins move from computational promise toward clinical reality, the challenge is no longer simply generating protein candidates, but understanding which molecules possess the stability, functionality, developability and manufacturability required for successful therapeutic translation, at scale. 

The inaugural Protein Design & Engineering in Biopharma Summit arrives, bringing together 80+ carefully selected leaders across protein engineering, structural biology, computational biology, biophysics, developability and biologics R&D. Unlike broader AI, biologics or drug discovery meetings, this highly technical and industry-focused forum provides a rare opportunity to examine the entire Design-Build-Test-Learn cycle, from rational and de novo design through experimental validation, protein characterization, optimization and translational development. 

Through practical case studies and peer-led discussion, attendees will benchmark integrated computational and wet-lab workflows, explore strategies to improve design predictability, and accelerate iteration cycles across antibodies, enzymes, mini-proteins, vaccines and next-generation biologics. Join the scientists defining the future of therapeutic protein engineering and leave with actionable insights, meaningful collaborations and proven approaches to translate better protein designs into successful therapeutics.